ディアシルフロキサンは,GPX4を共性的に阻害するマスクされたニトリル酸化物である
John K Eaton1, Richard A Ruberto1, Anneke Kramm1
1Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States.
Journal of the American Chemical Society
|December 17, 2019
まとめ
ディアシルフロキサンは,グルタチオン過酸化酵素4 (GPX4) を共性的に阻害する. この発見は,薬剤耐性がんにおける重要なタンパク質であるGPX4を標的とする新しいメカニズムを提供し,治療の選択肢を広げています.
科学分野:
- 薬剤化学
- 生物化学
- 腫瘍学
背景:
- グルタチオンペロキシダゼ4 (GPX4) は,特に薬剤耐性がんの治療対象として難しいものです.
- 現在のGPX4阻害剤は,主に,触媒性セレノシステイン残基の共価変異のためにクロロアセタミド分子を使用します.
- 多種多様なGPX4阻害剤は,この酵素を標的とする新しい電離弾頭を発見した.
研究 の 目的:
- 新しい共性GPX4阻害剤を発見し,特徴づけること.
- ダイアシルフロキサンがGPX4阻害体として作用する分子メカニズムの解明
- GPX4を標的とする新しい反応群を探求する.
主な方法:
- ダイアシルフロキサンの合成と特徴付け
- GPX4抑制を評価する生化学的測定法
- 独特の反応性と有効性を評価するための細胞測定.
主要な成果:
- ディアシルフロキサンは,マスクされたニトリル酸化物前薬として機能する.
- これらの化合物は,異なる細胞および生化学反応性を持つGPX4を共性的に阻害する.
- このメカニズムは,既存のGPX4阻害剤と異なる.
結論:
- ディアシルフロキサンはGPX4阻害剤の新種である.
- この研究は,フロキサン生物活性の新しい分子機構を明らかにした.
- 発見はGPX4を標的とする化学戦略のレパートリーを拡大する.
関連する概念動画
GPCRs Regulate Adenylyl Cylase Activity
7.1K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.1K
GPCR Desensitization
7.8K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.8K
Eukaryotic Transcription Inhibitors
10.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.8K
Dipeptidyl Peptidase 4 Inhibitors
519
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
519
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
856
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
856
Transducer Mechanism: G Protein–Coupled Receptors
3.7K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
3.7K


